---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-100755"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:42:57.330146+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Natera Q2 revenue up 64% to $142M; guides FY2021 revenue to $600-620M

## Summary
- Product revenue $137.2M, +70.7% YoY; processed 375,700 tests, +60.5%.
- Net loss $116.0M ($1.32/share) vs $59.6M ($0.75) a year ago.
- Raised 2021 revenue guidance to $600-620M from $550-575M (second increase).
- Completed $551.2M net follow-on equity offering in July 2021.
- CMS awarded ADLT status for Signatera MRD test; GSK phase III trial announced.

## SEC filing metadata
- accession: 0001104659-21-100755
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465921100755/0001104659-21-100755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465921100755/tm2124237d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-100755
- JSON: https://secwatch.observer/filing/0001104659-21-100755.json
- Plain text: https://secwatch.observer/filing/0001104659-21-100755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.